EXTON, Pa., March 15 /PRNewswire-FirstCall/ -- Kensey Nash Corporation today announced that it will provide an update on the anticipated 510(k) clearance by the U.S. Food and Drug Administration (FDA) of the triActiv(R) System. In addition, the Company will update guidance for fiscal year 2005 as well as an outlook for its fiscal year 2006. This information will be released after 4:00 pm eastern time on Wednesday, March 16, 2005.
Joe Kaufmann, President and CEO, will be hosting a conference call to discuss the update on Thursday, March 17, 2005 at 8:30 am eastern time.
To participate in the teleconference call, dial 1-480-629-9566. The teleconference will also be available for replay starting Thursday, March 17, 2005 at 12:00 pm eastern through Tuesday, March 22, 2005 at 11:59 pm eastern time by dialing 1-800-475-6701 with an access code of 774586.
Individuals interested in listening to the teleconference may also do so over the Internet at http://www.kenseynash.com/. To listen to the live call, please go to the http://www.kenseynash.com/ website and choose the Investor Relations page. Please allow 15 minutes prior to the start of the call to register, download and install any necessary software. A replay of the teleconference will be archived on the http://www.kenseynash.com/ website and may be accessed following the teleconference.
About Kensey Nash Corporation. Kensey Nash Corporation is a leading developer and manufacturer of absorbable biomaterials-based products with applications in the cardiology, orthopedics, spine, drug and biologics delivery, periodontal/dental, surgical and wound care markets. The Company was a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(R) Vascular Closure Device, which is licensed to St. Jude Medical, Inc. The Company's triActiv(R) Balloon Protected Flush Extraction System for the treatment of saphenous vein graft disease is commercialized in the European Union. The Company has submitted an application for 510(k) clearance for its triActiv(R) System to the U.S. Food and Drug Administration, following the completion of a major clinical study.
Kensey Nash CorporationCONTACT: Joseph W. Kaufmann, President and Chief Executive Officer ofKensey Nash Corporation, +1-610-524-0188
Web site: http://www.kenseynash.com/